Phathom Pharma Q1 net rev $58.3M (+104% YoY); maintains FY 2026 op profitability guidance

Phathom Pharmaceuticals, Inc.

2026-Q1 EPS reported -$0.37 revenue$58,301,000

Q1 net revenues $58.3M vs $28.5M YoY; net loss $30.4M vs $94.3M YoY.
Non-GAAP operating expenses $56.2M, down ~43% YoY; cash and equivalents $180.9M.
~1.35M total VOQUEZNA prescriptions filled to date; Q1 covered prescriptions up 91% YoY.
FY 2026 guidance: net rev $320-345M, non-GAAP op ex $235-255M; op profitability expected Q3 2026.
EoE phase 2 trial (pHalcon-EoE-201) topline results expected late Q4 2026/early Q1 2027.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.98

Phathom Pharmaceuticals, Inc. reported the first quarter ended March 31, 2026 results: revenue $58.3 million. Guidance reaffirmed.

Period: the first quarter ended March 31, 2026
Revenue: $58.3 million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Exhibit 99.1 Phathom Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update • ~1.35 million total VOQUEZNA ® prescriptions filled to date • $58.3 million in Q1 net revenues, a 104% increase year-over-year • Q1 operating expenses of $61.8 million; non-GAAP operating expenses of $56.2 million and net cash usage of ~$15 million,

View on SEC.gov

1427 earnings releases filed in the last 30 days. Browse all earnings releases →

Phathom Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-193945

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.